| human | Q5 |
| P9984 | CANTIC ID | 981058520067606706 |
| P227 | GND ID | 1013052366 |
| P269 | IdRef ID | 12757803X |
| P213 | ISNI | 0000000371097420 |
| P244 | Library of Congress authority ID | nb2008008261 |
| P3835 | Mendeley person ID | manuel-ramos-casals |
| P8189 | National Library of Israel J9U ID | 987007315730205171 |
| P950 | National Library of Spain ID | XX964051 |
| P1207 | NUKAT ID | n2012074325 |
| P496 | ORCID iD | 0000-0001-5709-6734 |
| P1153 | Scopus author ID | 7004350246 |
| P11686 | University of Barcelona authority ID | 981058520067606706 |
| P1580 | University of Barcelona authority ID (former scheme) | a1336120 |
| P214 | VIAF ID | 250567604 |
| P10832 | WorldCat Entities ID | E39PBJyRxr6MMxWdDgdmY7wwG3 |
| P69 | educated at | University of Barcelona | Q219615 |
| P108 | employer | Hospital Clinic of Barcelona | Q2371388 |
| P735 | given name | Manuel | Q11113719 |
| Manuel | Q11113719 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q38409092 | A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach |
| Q73298637 | A quality of life study in women with systemic lupus erythematosus and its relation to disease activity |
| Q37326300 | A systematic review of the off-label use of biological therapies in systemic autoimmune diseases |
| Q30356635 | Abdominal aortic aneurysm screening program using hand-held ultrasound in primary healthcare. |
| Q37326295 | Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature |
| Q38167486 | Adult haemophagocytic syndrome |
| Q36951011 | Advances in lupus and Sjögren's syndrome: a tribute to Josep Font |
| Q38232660 | Advances in the understanding and treatment of systemic complications in Sjögren's syndrome. |
| Q56907450 | Afección del sistema nervioso central en el síndrome de Sjögren primario |
| Q45345442 | American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort |
| Q38170245 | Annular erythema in primary Sjogren's syndrome: description of 43 non-Asian cases. |
| Q35552703 | Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy |
| Q36300105 | Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature |
| Q78108988 | Antineutrophil cytoplasmic antibodies in primary Sjögren's syndrome: prevalence and clinical significance |
| Q90465816 | Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort |
| Q33239982 | Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients |
| Q35553410 | Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients |
| Q56907552 | Asociación de síndrome de Sjögren, tiroiditis autoinmune, sarcoidosis, cirrosis biliar primaria y amiloidosis primaria en una misma paciente |
| Q56907718 | Association of antiphospholipid antibodies with retinalvascular disease in systemic lupus erythematosus |
| Q56907559 | Association of mannose-binding lectin gene polymorphisms with antiphospholipid syndrome, cardiovascular disease and chronic damage in patients with systemic lupus erythematosus |
| Q45176835 | Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases |
| Q36332517 | Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus |
| Q38601893 | Autoimmune Diseases Induced By Biological Agents. A review of 12731 cases (BIOGEAS Registry). |
| Q56907567 | Autoimmune Diseases Induced by TNF-Targeted Therapies |
| Q38695221 | Autoimmune congenital heart block: complex and unusual situations |
| Q56907501 | Autoimmune diseases in the elderly: systemic lupus erythematosus and Sjögren’s syndrome |
| Q37333105 | Autoimmune diseases induced by TNF-targeted therapies |
| Q37620986 | Autoimmune diseases induced by biological agents: a double-edged sword? |
| Q35135284 | Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly |
| Q37965313 | B-cell depleting agents for ANCA vasculitides: a new therapeutic approach |
| Q37586344 | B-cell-depleting therapy in systemic lupus erythematosus |
| Q37877458 | Basophils, IgE, and autoantibody-mediated kidney disease |
| Q73397066 | Bcl-2 oncogene (B cell lymphoma/leukemia-2) levels correlate with systemic lupus erythematosus disease activity |
| Q38056825 | Biologics-induced autoimmune diseases |
| Q36811755 | Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort |
| Q31846096 | Cardiovascular risk factors and the long-term outcome of lupus nephritis |
| Q56907410 | Cardiovascular risk factors in primary Sjögren's syndrome: a case-control study in 624 patients |
| Q35214718 | Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functions |
| Q35953379 | Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases |
| Q43660395 | Catastrophic antiphospholipid syndrome: clinical description and triggering factors in 8 patients. |
| Q34435380 | Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients |
| Q36951067 | Catastrophic antiphospholipid syndrome: lessons from the "CAPS Registry"--a tribute to the late Josep Font |
| Q47556201 | Cerebrovascular Events in Systemic Lupus Erythematosus |
| Q56907510 | Chapter 16 Extrahepatic Manifestations in Patients with Chronic Hepatitis C Virus Infection |
| Q56907516 | Chapter 7 Digestive Involvement in Primary Sjögren's Syndrome |
| Q56907522 | Chapter 9 Adrenal Involvement in Systemic Autoimmune Diseases |
| Q33568158 | Characterization and risk estimate of cancer in patients with primary Sjögren syndrome |
| Q43035565 | Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection |
| Q45385102 | Chronic hepatitis B virus infection in Sjögren's syndrome. Prevalence and clinical significance in 603 patients |
| Q56907597 | Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren's syndrome |
| Q35549218 | Circulating concentrations of soluble L-selectin (CD62L) in patients with primary Sjögren's syndrome |
| Q74327174 | Circulating levels of Th1/Th2 cytokines in patients with primary Sjögren's syndrome: correlation with clinical and immunological features |
| Q44165982 | Circulating monoclonal immunoglobulins in Sjögren syndrome: prevalence and clinical significance in 237 patients |
| Q56907455 | Clasificación de la fibromialgia. Revisión sistemática de la literatura |
| Q53892066 | Classification and characterisation of peripheral neuropathies in 102 patients with primary Sjögren's syndrome. |
| Q45235101 | Classification criteria for Sjogren's syndrome: we actually need to definitively resolve the long debate on the issue |
| Q56907418 | Clinical and Prognostic Significance of Parotid Scintigraphy in 405 Patients with Primary Sjogren's Syndrome |
| Q30560952 | Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort |
| Q37356697 | Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review |
| Q33360085 | Clinical features related to antiphospholipid syndrome in patients with chronic viral infections (hepatitis C virus/HIV infection): description of 82 cases |
| Q37654616 | Clinical guidelines for the management of acute viral infections in patients with systemic lupus erythematosus |
| Q90995706 | Clinically-useful serum biomarkers for diagnosis and prognosis of sarcoidosis |
| Q33359656 | Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center |
| Q43050231 | Coeliac disease associated with systemic sclerosis |
| Q37604421 | Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients |
| Q41067588 | Complexity, comorbidity, and health care costs associated with chronic widespread pain in primary care |
| Q93110379 | Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus |
| Q59355453 | Cryoglobulinaemia |
| Q43040761 | Cryoglobulinaemia associated with hepatitis C virus: influence of HCV genotypes, HCV-RNA viraemia and HIV coinfection |
| Q40785165 | Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients |
| Q56907690 | Cryoglobulinemia |
| Q34485578 | Cryoglobulinemia in primary Sjögren's syndrome: prevalence and clinical characteristics in a series of 115 patients |
| Q56907681 | Cryoglobulinemia in systemic lupus erythematosus: Prevalence and clinical characteristics in a series of 122 patients |
| Q34407224 | Cryoglobulinemic disease |
| Q56907652 | Cutaneous Vasculitis in Primary Sjögren Syndrome |
| Q51597491 | Cutaneous lupus erythematosus: clinical and immunological study of 308 patients stratified by gender. |
| Q56453023 | Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients |
| Q47631214 | Cytokines as therapeutic targets in primary Sjögren syndrome |
| Q33333384 | Cytopenia and past human parvovirus B19 infection in patients with primary Sjögren's syndrome |
| Q39081726 | Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). |
| Q28212959 | Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients |
| Q39791068 | Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies |
| Q35906036 | Diagnosis of Liver Involvement in Primary Sjögren Syndrome |
| Q38542540 | Diagnostic Approach to the Complexity of IgG4-Related Disease |
| Q33366327 | Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients |
| Q37846349 | EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome |
| Q26778262 | EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide |
| Q91043661 | EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies |
| Q38675817 | Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations |
| Q90690732 | Economic evaluation of damage accrual in an international SLE inception cohort using a multi-state model approach |
| Q47385774 | Economic evaluation of lupus nephritis in the Systemic Lupus International Collaborating Clinics inception cohort using a multistate model approach |
| Q91368809 | Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome |
| Q34060110 | Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts |
| Q30823425 | Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort |
| Q36857229 | Emerging biological therapies in primary Sjogren's syndrome |
| Q44526860 | Erratum to: Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects |
| Q85896052 | Etiopathogenic role of surfactant protein d in the clinical and immunological expression of primary Sjögren syndrome |
| Q91640246 | Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus |
| Q39144671 | Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection |
| Q56907537 | Evolución y pronóstico del paciente con síndrome de Sjögren primario |
| Q36163462 | Extrahepatic manifestations in patients with chronic hepatitis C virus infection |
| Q44505676 | Extrahepatic manifestations in patients with chronic infections due to the hepatitis C virus |
| Q28608340 | Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort |
| Q47557472 | Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort |
| Q30923489 | Google-driven search for big data in autoimmune geoepidemiology: analysis of 394,827 patients with systemic autoimmune diseases |
| Q56907336 | Granulocytes |
| Q44915681 | Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study |
| Q56907665 | Hematologic malignancies in patients with cryoglobulinemia: Association with autoimmune and chronic viral diseases |
| Q45362101 | Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases |
| Q37317548 | Hepatitis C virus and Sjögren's syndrome: trigger or mimic? |
| Q35547132 | Hepatitis C virus infection in 'primary' Sjögren's syndrome: prevalence and clinical significance in a series of 90 patients |
| Q34154745 | Hepatitis C virus infection mimicking primary Sjögren syndrome. A clinical and immunologic description of 35 cases |
| Q45739101 | Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus |
| Q36010595 | Hepatitis C virus, Sjögren's syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer |
| Q27477922 | Hepatitis G virus infection in primary Sjögren's syndrome: analysis in a series of 100 patients |
| Q74523535 | High circulating levels of soluble scavenger receptors (sCD5 and sCD6) in patients with primary Sjögren's syndrome |
| Q41917824 | How are we treating our systemic patients with primary Sjögren syndrome? Analysis of 1120 patients |
| Q36060723 | How hepatitis C virus modifies the immunological profile of Sjögren syndrome: analysis of 783 patients |
| Q92692068 | How the Frequency and Phenotype of Sarcoidosis is Driven by Environmental Determinants |
| Q56907636 | Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome |
| Q33363684 | Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients |
| Q39019629 | IgG4-related disease: Advances in the diagnosis and treatment |
| Q30791606 | Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort |
| Q56907309 | Incorrect Values for Intractable and Cluster Headaches at Enrollment Shown in Figure 1 and Incorrect Prevalence of Headache at Ten Years in Text of the Article by Hanly et al (Arthritis Rheum, November 2013) |
| Q56907703 | Increased serum levels of soluble L-selectin (CD62L) in patients with active systemic lupus erythematosus (SLE) |
| Q41050054 | Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies |
| Q54452633 | Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. |
| Q53292752 | Influence of clinical and immunological parameters on the health-related quality of life of patients with primary Sjögren's syndrome. |
| Q31145428 | Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium |
| Q38957792 | International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement |
| Q39175159 | International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement |
| Q56907397 | Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases |
| Q36701151 | Intestinal involvement secondary to the antiphospholipid syndrome (APS): clinical and immunologic characteristics of 97 patients: comparison of classic and catastrophic APS. |
| Q38656396 | Introducing treat-to-target strategies of autoimmune extrahepatic manifestations of chronic hepatitis C virus infection |
| Q42856259 | Is hepatitis C virus a sialotropic virus? |
| Q38094529 | Is it time for biosimilars in autoimmune diseases? |
| Q36997275 | Lessons from diseases mimicking Sjögren's syndrome |
| Q73063639 | Lessons from the "Euro-Lupus Cohort" |
| Q56907588 | Letter To The Editor |
| Q36008973 | Life-Threatening Cryoglobulinemic Patients With Hepatitis C: Clinical Description and Outcome of 279 Patients |
| Q40469268 | Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. |
| Q53821067 | Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure. |
| Q90681087 | Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort |
| Q40568240 | Low values of creatine kinase in systemic lupus erythematosus. Clinical significance in 300 patients. |
| Q56907465 | Mannose-binding lectin-low genotypes are associated with milder systemic and immunological disease expression in primary Sjogren's syndrome |
| Q33901848 | Mixed cryoglobulinemia: new concepts |
| Q37832130 | Monoclonal antibody therapy-associated neurological disorders |
| Q56907365 | Monoclonal gammopathy related to Sjögren syndrome: A key marker of disease prognosis and outcomes |
| Q35797933 | Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study |
| Q33357081 | Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients |
| Q56907610 | Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients |
| Q36670021 | Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors |
| Q36085885 | Mycophenolate mofetil in patients with hepatitis C virus infection |
| Q40238844 | New approaches in Sjögren's syndrome therapy |
| Q33587613 | Nodular regenerative hyperplasia of the liver and antiphospholipid antibodies: report of two cases and review of the literature |
| Q39367854 | Off-label use of rituximab for systemic lupus erythematosus in Europe |
| Q45085614 | Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases |
| Q64893122 | Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. |
| Q37988207 | Outcome measures for primary Sjögren's syndrome |
| Q38177429 | Outcome measures for primary Sjögren's syndrome: a comprehensive review |
| Q42912989 | Outcomes in biopsy-proven lupus nephritis: evaluation of 190 white patients from a single center |
| Q92474679 | Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study |
| Q56907577 | Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors |
| Q90832501 | Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index |
| Q101352178 | Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) |
| Q35012168 | Preliminary classification criteria for the cryoglobulinaemic vasculitis |
| Q56907473 | Prevalence and Clinical Relevance of Autoimmune Neutropenia in Patients with Primary Sjögren's Syndrome |
| Q41941085 | Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival |
| Q38018910 | Primary Sjogren syndrome. |
| Q56907530 | Primary Sjogren's syndrome |
| Q33380356 | Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients |
| Q38076460 | Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions. |
| Q34778403 | Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients |
| Q34778410 | Primary Sjögren syndrome: hematologic patterns of disease expression |
| Q43846952 | Primary Sjögren's syndrome and lymphatic proliferation |
| Q33893087 | Primary Sjögren's syndrome in men: clinical and immunological characteristics |
| Q56907726 | Primary Sjögren's syndrome in the elderly: clinical and immunological characteristics |
| Q36163155 | Primary Sjögren's syndrome: current and emergent aetiopathogenic concepts |
| Q35555323 | Primary Sjögren's syndrome: new clinical and therapeutic concepts |
| Q33330667 | Primary antiphospholipid syndrome evolving into systemic lupus erythematosus: a report of 3 new cases and a review of the literature |
| Q58804361 | Prognostic Factors of Death in 151 Adults With Hemophagocytic Syndrome: Etiopathogenically Driven Analysis |
| Q34087831 | Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus |
| Q51074622 | Psychiatric and psychosocial disorders in patients with systemic lupus erythematosus: a longitudinal study of active and inactive stages of the disease. |
| Q58093032 | Psychosis in Systemic Lupus Erythematosus |
| Q37870503 | Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases |
| Q56907373 | Punctal occlusion in Sjögren's syndrome needs clarification |
| Q35176768 | Pure sensory neuropathy in primary Sjögren's syndrome. Longterm prospective followup and review of the literature. |
| Q35617617 | Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label |
| Q39599564 | Raynaud's phenomenon in primary Sjögren's syndrome. Prevalence and clinical characteristics in a series of 320 patients. |
| Q56907345 | Recomendaciones sobre el uso de belimumab en el lupus eritematoso sistémico. Guía de Práctica Clínica GEAS-SEMI |
| Q40012091 | Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status. |
| Q56907620 | Resultados del tratamiento con pilocarpina oral en 100 pacientes con síndrome de Sjögren primario |
| Q56907425 | Revisión sistemática del uso de adalimumab en enfermedades autoinmunes. Eficacia y seguridad en 54 pacientes |
| Q56907482 | Rituximab and lupus: Good in real life, bad in controlled trials. comment on the article by Lu et al |
| Q37541561 | Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases |
| Q37737138 | Rituximab therapy in lupus nephritis: current clinical evidence |
| Q46089672 | Role of CD5/CD5L interactions in the homeostasis of regulatory lymphocyte subpopulations and the control of autoimmune disorders |
| Q37226689 | SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus |
| Q36066887 | Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases |
| Q35695309 | Sarcoidosis or Sjögren syndrome? Clues to defining mimicry or coexistence in 59 cases |
| Q38798146 | Sarcoidosis: an update on current pharmacotherapy options and future directions |
| Q36307429 | Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study |
| Q33346990 | Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases |
| Q55970262 | Sjögren syndrome |
| Q43846314 | Sjögren syndrome and hepatitis C virus infection |
| Q45501012 | Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases |
| Q40385292 | Sjögren syndrome or sjögren disease? The histological and immunological bias caused by the 2002 criteria |
| Q56907489 | Sjögren's Syndrome |
| Q33651774 | Sjögren's syndrome and hepatitis C virus |
| Q90820946 | Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus |
| Q33334858 | Splenectomy for refractory Evans' syndrome associated with antiphospholipid antibodies: report of two cases. |
| Q45122047 | Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis |
| Q48249597 | Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients |
| Q45461798 | Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (the HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases |
| Q35852882 | Systemic autoimmune diseases in elderly patients: atypical presentation and association with neoplasia |
| Q45385300 | Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). |
| Q50484229 | Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). |
| Q35548094 | Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults |
| Q36399103 | Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". |
| Q56907643 | Síndrome de Sjögren. Nuevas perspectivas terapéuticas |
| Q37729828 | Targeted therapy for systemic sclerosis: how close are we? |
| Q56907291 | Terapia biológica en pacientes con miopatía inflamatoria idiopática |
| Q56907441 | Terapias biológicas en las enfermedades autoinmunes sistémicas: ¿se cumplen las expectativas? |
| Q45731018 | Th1/Th2 cytokine imbalance in patients with Sjögren syndrome secondary to hepatitis C virus infection |
| Q45332999 | The B-lymphocyte stimulator connection in Sjogren's syndrome |
| Q48137227 | The Burden of Comorbidity and Complexity in Sarcoidosis: Impact of Associated Chronic Diseases |
| Q37988167 | The DWEYS peptide in systemic lupus erythematosus |
| Q35636571 | The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients |
| Q38242726 | The clinical spectrum of IgG4-related disease |
| Q38387739 | The clinical spectrum of autoimmune congenital heart block |
| Q37922370 | The cryoglobulinaemias |
| Q37082037 | The frequency and outcome of lupus nephritis: results from an international inception cohort study |
| Q56907319 | The ill endothelium: how atherosclerosis begins in lupus |
| Q33393448 | The importance of laboratory in the diagnosis in Sjogren's syndrome |
| Q33372729 | The overlap of Sjögren's syndrome with other systemic autoimmune diseases |
| Q40237986 | The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients |
| Q74712378 | The role of interleukin-10 promoter polymorphisms in the clinical expression of primary Sjögren's syndrome |
| Q38883428 | Therapeutic approach to IgG4-related disease: A systematic review |
| Q35121285 | Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection |
| Q37829817 | Therapeutic targeting of B cells for rheumatic autoimmune diseases |
| Q45371578 | Therapy: Are TNF blockers safe for patients with hepatitis B virus infection? |
| Q56907712 | Thyroid Disease in Primary Sjögren Syndrome: Study in a Series of 160 Patients |
| Q36844733 | Thyroid disease in Sjögren's syndrome. |
| Q44498935 | Topical and systemic medications for the treatment of primary Sjögren's syndrome. |
| Q37483915 | Transgenic expression of soluble human CD5 enhances experimentally-induced autoimmune and anti-tumoral immune responses |
| Q56907388 | Tratamiento depletivo de células B en enfermedades autoinmunitarias sistémicas. Recomendaciones de uso en la práctica clínica |
| Q38795404 | Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects |
| Q43486371 | Treatment of B-cell lymphoma with rituximab in two patients with Sjögren's syndrome associated with hepatitis C virus infection |
| Q37776086 | Treatment of primary Sjögren syndrome: a systematic review |
| Q56907356 | Trial of SLE therapies in real-world settings |
| Q35679988 | Triple association between hepatitis C virus infection, systemic autoimmune diseases, and B cell lymphoma. |
| Q91502625 | Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen |
| Q44016941 | Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjögren's syndrome. Correlation with clinical, immunological and histological features |
| Q52880103 | Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). |
| Q42208172 | Validation of the classification criteria for cryoglobulinaemic vasculitis |
| Q35555909 | Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome |
| Q51810963 | Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. |
| Q37324878 | Vasculitis induced by tumor necrosis factor-targeted therapies |
| Q35172132 | Viral etiopathogenesis of Sjögren's syndrome: role of the hepatitis C virus |
| Q40511348 | Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals |
| Q56907545 | Viruses and lupus: the viral hypothesis |
| Q48788608 | White matter abnormalities in primary Sjögren syndrome |
| Q44043516 | Young onset of primary Sjögren's syndrome: clinical and immunological characteristics |
| Q95809611 | [Belimumab in systemic lupus erythematosus: a guide for its use in the daily practice] |
| Q74064771 | [Clinical manifestations and immunology associated with chronic infection with hepatitis C virus] |
| Q50579666 | [Evolution of Sjögren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin]. |
| Q73291117 | [Mixed cryoglobulinemia. Essential?] |
| Q74043108 | [Prevalence and clinical significance of hepatitis C virus infection in systemic autoimmune diseases] |
| Q50932348 | [Primary Sjögren's syndrome: clinical and immunologic study of 80 patients] |
| Q53514252 | [Sacroiliitis and Behçet disease] |
Search more.